Telix Pharmaceuticals (TLPPF) Common Equity (2023 - 2026)

Telix Pharmaceuticals (TLPPF) has reported Common Equity for 4 consecutive years, with $487.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity changed N/A year-over-year to $487.7 million in Q2 2026; TTM through Jun 2026 was $487.7 million, a N/A change from a year earlier, with the FY2025 full-year figure at $415.4 million, up 17.69% from the prior year.
• Common Equity was $487.7 million for Q2 2026 at Telix Pharmaceuticals, up from $415.4 million in the prior quarter.
• Over five years, Common Equity peaked at $487.7 million in Q2 2026 and troughed at $96.9 million in Q4 2023.
• A 4-year average of $342.9 million and a median of $393.5 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity soared 283.32% in 2024 and climbed 11.78% in 2025, its largest moves.
• Over 4 years, Common Equity stood at $96.9 million in 2023, then soared by 283.32% to $371.6 million in 2024, then increased by 11.78% to $415.4 million in 2025, then advanced by 17.41% to $487.7 million in 2026.
• The last three Common Equity figures came in at $487.7 million (Q2 2026), $415.4 million (Q4 2025), and $371.6 million (Q4 2024), per Business Quant data.